title: [Adverse events related to systemic treatment using Glucantime for cutaneous leishmaniasis: a report from Tunisia].
abstract: Glucantime is the firstline treatment for cutaneous leishmaniasis in Tunisia. Adverse effects related to systemic administration of Glucantime are frequent. The purpose of this retrospective study was to review the files of 53 patients who were treated for cutaneous leishmaniasis using meglumine antimoniate at a dose of 60 mg/kg/day for 15 days during the period between 1998 and 2007. Adverse effects were observed in 5 men and 4 women with an average age of 40.8 years. Antimony intolerance occurred in 8 patients and stibio-intoxication occurred in 4. Glucantime was considered as the most likely cause of adverse effects in 6 patients and as the plausible cause in 3 patients. Fever was the most frequent complication of antimony intolerance followed by cough, myalgia, and cutaneous lesions. Hepatic cytolysis was the most frequent sign of stibio-intoxication. Asymptomatic elevation of amylase level to 108 UI/l was observed in one case. The most serious complication was acute toxic kidney failure on the 15th day of treatment. The incidence of adverse events to Glucantime ranges from 16% to 59%. The most severe complication is acute renal failure on the 15th day of treatment, as observed in one patient in this series. Patient status must be monitored by performing laboratory tests at the beginning and end of the treatment. Since cutaneous leishmaniasis observed in Tunisia is a self-healing dermatosis that never results in sequels, treatment with Glucantime should be discontinued in any patient who develops suspicious symptoms.
authors.affiliation: Service de dermatologie, Hôpital Habib Thameur Tunis, Tunisie. rym.benmously@rns.tn
authors.forename: Benmously R
authors.initials: BR
authors.lastname: Mlika
authors.forename: S
authors.initials: S
authors.lastname: El Aïdli
authors.forename: M
authors.initials: M
authors.lastname: Ben Brahim
authors.forename: T
authors.initials: T
authors.lastname: Badri
authors.forename: S
authors.initials: S
authors.lastname: Chouk
authors.forename: S
authors.initials: S
authors.lastname: Ben Jannet
authors.forename: H
authors.initials: H
authors.lastname: Marrrak
authors.forename: R
authors.initials: R
authors.lastname: Daghfous
authors.forename: I
authors.initials: I
authors.lastname: Mokhtar
authors.forename: S
authors.initials: S
authors.lastname: Fenniche
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000981:Antiprotozoal Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000009:adverse effects*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects*; D012189:Retrospective Studies; D014416:Tunisia; D055815:Young Adult
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate